Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: A review of literature.

Related Articles

Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: A review of literature.

J Dermatolog Treat. 2016 Dec 26;:1-32

Authors: Samadi A, Ahmad Nasrollahi S, Hashemi A, Nassiri-Kashani M, Firooz A

Abstract
Janus kinase family (JAKs) has recently attracted the attention of many researchers, and several JAK inhibitor drugs have been developed targeting different members of the JAK family. Tofacitinib and ruxolitinib are U.S. FDA approved drugs in this family approved for rheumatoid arthritis and myeloproliferative diseases, respectively. Dysregulation of JAK/STAT pathway is also involved in many skin diseases, specifically inflammatory disorders. We overview the JAK/STAT signaling pathway and its involvement in skin diseases. We also review clinical studies of JAK inhibitors in field of dermatology, including psoriasis, atopic dermatitis, alopecia areata and vitiligo. Although the available evidence shows promising results, it is still too early draw a firm conclusion about the place of these drugs in dermatological treatment.

PMID: 28024126 [PubMed - as supplied by publisher]

http://ift.tt/2iar0f6